Cory Renauer is an Analyst at BioSpace. He focuses on investing in healthcare and fintech stocks, aiming to simplify complex financial topics to empower everyday investors in making informed decisions. Cory's insights have been featured in prominent outlets including Yahoo Finance, Nasdaq, and The Motley Fool.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Cory's articles primarily focus on investment analysis, with a particular emphasis on healthcare and pharmaceutical companies, as well as high-yield dividend stocks. He also covers stock market trends and specific stock recommendations based on data-driven analyses.
For effective outreach to Cory Renauer, consider providing data-backed insights into the performance of healthcare and pharmaceutical companies or high-yield dividend stocks. If you have expertise in analyzing investment opportunities within these sectors, particularly with reference to specific stocks or broader market trends, your pitch is likely to be well-received.
It's important that any information provided is backed by credible data and rigorous analysis given Cory's strong reliance on cited data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Specialty insurer RLI, known for its diverse coverage portfolio, reported a notable insider buy following a year of share price declines.
After a year of steep share price declines, this specialty insurance provider reports a notable insider buy amid ongoing market challenges.
By: Cory Renauer
This biopharma firm, focused on therapies for autoimmune diseases, reported a recent insider buy amid a year of strong share performance.
By: Cory Renauer
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.
By: Cory Renauer
Focused on gene and cell therapies, this biotech innovator reported a notable insider sale amid a year of exceptional share price gains.
By: Cory Renauer
Hinge Health, a digital musculoskeletal care provider, reported a notable insider sale amid strong one-year share price gains.
This global oilfield services provider saw insider buying after a year of standout share gains and continued expansion across key markets.
By: Cory Renauer
This animal health provider, serving global livestock markets, reported a notable insider buy in its latest SEC filing.
By: Cory Renauer
This offshore drilling contractor saw a recent insider buy as it maintains a global presence serving major and independent energy clients.
By: Cory Renauer
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
